Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference17 articles.
1. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911. Accessed 6 Apr 2020. https://doi.org/10.1038/s41467-018-04252-2.
2. Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas from encounter with a mysterious repeated sequence to genome editing technology. J Bacteriol. 2018;200(7):e00580-17. https://doi.org/10.1128/JB.00580-17.
3. Liu J, Zhou G, Zhang L, Zhao Q. Building potent chimeric antigen receptor T cells with CRISPR genome editing. Front Immunol. 2019;10:456. https://doi.org/10.3389/fimmu.2019.00456.
4. Grant EV. FDA regulation of clinical application of CRISPR-CAS gene-editing technology. Food Drug Law J. 2016. https://www.fdli.org/wp-content/uploads/2017/01/FDLJ-71-4-fda-regulation-clinical-applications-crispr-cas-22115661.pdf.
5. Lenzi RN, Altevogt BM, Gostin LO. Oversight and review of clinical gene transfer protocols: assessing the role of the Recombinant DNA Advisory Committee. Oversight of Gene Transfer Research. Committee on the Independent Review and Assessment of the Activities of the NIH Recombinant DNA Advisory Committee; Board on Health Sciences Policy; Institute of Medicine; 2014. https://www.ncbi.nlm.nih.gov/books/NBK195894/.